#BEGIN_DRUGCARD DB00348

# AHFS_Codes:
Not Available

# ATC_Codes:
A16AX04

# Absorption:
The capsule and liquid formulations are bioequivalent in both the plasma concentration-time curve and maximum plasma concentration (Cmax).

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Orfadin

# CAS_Registry_Number:
104206-65-7

# ChEBI_ID:
50378

# Chemical_Formula:
C14H10F3NO5

# Chemical_IUPAC_Name:
2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. [Wikipedia]

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Enzyme Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.6

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Nitisinone

# HET_ID:
Not Available

# Half_Life:
~54 hours

# InChI_Identifier:
InChI=1S/C14H10F3NO5/c15-14(16,17)7-4-5-8(9(6-7)18(22)23)13(21)12-10(19)2-1-3-11(12)20/h4-6,12H,1-3H2

# InChI_Key:
InChIKey=OUBCNLGXQFSTLU-UHFFFAOYSA-N

# Indication:
Used as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
348

# Mechanism_Of_Action:
Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolyase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with hereditary tyrosinemia type 1 (HT-1), nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
329.2281

# Molecular_Weight_Mono:
329.05110705

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164777037

# Pharmacology:
Hereditary tyrosinemia type 1 occurs due to a deficiency in fumarylacetoacetase (FAH), the final enzyme in the tyrosine catabolic pathway. Nitisinone inhibits catabolism of tyrosine by preventing the catabolic intermediates. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate, a neurotoxin responsible for the porphyric crises characteristic of HT-1.

# Predicted_LogP_Hydrophobicity:
2.06

# Predicted_LogS:
-4.6

# Predicted_Water_Solubility:
8.11e-03 g/l

# Primary_Accession_No:
DB00348

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
115355

# PubChem_Substance_ID:
46507380

# RxList_Link:
http://www.rxlist.com/cgi/generic/orfadin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01141

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[O-][N+](=O)C1=C(C=CC(=C1)C(F)(F)F)C(=O)C1C(=O)CCCC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects include elevated plasma levels of this amino acid, hepatic and liver failure.

# Update_Date:
2013-02-08 16:19:16 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Nitisinone

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
12142814	Hanauske-Abel HM, Popowicz A, Remotti H, Newfield RS, Levy J: Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism. J Pediatr Gastroenterol Nutr. 2002 Jul;35(1):73-8.
14668946	Yang DY: 4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target. Drug News Perspect. 2003 Oct;16(8):493-6.
15931360	Fisher AA, Davis MW: Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review. Clin Med Res. 2004 Nov;2(4):209-15.
18422479	Suwannarat P, O'Brien K, Perry MB, Sebring N, Bernardini I, Kaiser-Kupfer MI, Rubin BI, Tsilou E, Gerber LH, Gahl WA: Use of nitisinone in patients with alkaptonuria. Metabolism. 2005 Jun;54(6):719-28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15931605# Santra S, Baumann U: Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
HPD

# Drug_Target_1_GenBank_ID_Gene:
U29895

# Drug_Target_1_GenBank_ID_Protein:
3860238

# Drug_Target_1_GeneCard_ID:
HPD

# Drug_Target_1_Gene_Name:
HPD

# Drug_Target_1_Gene_Sequence:
>1182 bp
ATGACGACTTACAGTGACAAAGGGGCAAAGCCTGAGAGAGGCCGATTCCTCCACTTCCAC
TCTGTGACCTTCTGGGTTGGCAACGCCAAGCAGGCCGCGTCATTCTACTGCAGCAAGATG
GGCTTTGAACCTCTAGCCTACAGGGGCCTGGAGACCGGTTCCCGGGAGGTGGTCAGCCAT
GTAATCAAACAAGGGAAGATTGTGTTTGTCCTCTCCTCAGCGCTCAACCCCTGGAACAAA
GAGATGGGCGATCACCTGGTGAAACACGGTGACGGAGTGAAGGACATTGCGTTCGAGGTG
GAAGATTGTGACTACATCGTGCAGAAAGCACGGGAACGGGGCGCCAAAATCATGCGGGAG
CCCTGGGTAGAGCAAGACAAGTTTGGGAAGGTGAAGTTTGCTGTGCTGCAGACGTATGGG
GACACCACACACACCCTGGTGGAGAAGATGAACTACATCGGCCAATTCTTGCCTGGATAT
GAGCCCCCAGCGTTCATGGACCCCCTACTTCCTAAACTGCCCAAATGCAGTCTGGAGATG
ATCGACCACATTGTGGGAAACCAGCCTGATCAGGAGATGGTGTCCGCCTCCGAATGGTAC
CTGAAAAACCTGCAGTTCCACCGCTTCTGGTCCGTGGATGACACGCAGGTGCACACGGAA
TATAGCTCTCTGCGATCCATTGTGGTGGCCAACTATGAAGAGTCCATCAAGATGCCCATC
AATGAGCCAGCGCCTGGCAAGAAGAAGTCCCAGATCCAGGAATATGTGGACTATAACGGG
GGCGCTGGGGTCCAGCACATCGCTCTCAAGACCGAAGACATCATCACAGCGATTCGCCAC
TTGAGAGAGAGAGGCCTGGAGTTCTTATCTGTTCCCTCCACGTACTACAAACAACTGCGG
GAGAAGCTGAAGACGGCCAAGATCAAGGTGAAGGAGAACATTGATGCCCTGGAGGAGCTG
AAAATCCTGGTGGACTACGACGAGAAAGGCTACCTCCTGCAGATCTTCACCAAACCGGTG
CAGGACCGGCCCACGCTCTTCCTGGAAGTCATCCAGCGCCACAACCACCAGGGTTTTGGA
GCCGGCAACTTCAACTCACTGTTCAAGGCTTTCGAGGAGGAGCAGAACCTGCGGGGTAAC
CTCACCAACATGGAGACCAATGGGGTGGTGCCCGGCATGTAA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
10942115	Ruetschi U, Cerone R, Perez-Cerda C, Schiaffino MC, Standing S, Ugarte M, Holme E: Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III. Hum Genet. 2000 Jun;106(6):654-62.
11073718	Tomoeda K, Awata H, Matsuura T, Matsuda I, Ploechl E, Milovac T, Boneh A, Scott CR, Danks DM, Endo F: Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria. Mol Genet Metab. 2000 Nov;71(3):506-10.
7851880	Awata H, Endo F, Matsuda I: Structure of the human 4-hydroxyphenylpyruvic acid dioxygenase gene (HPD). Genomics. 1994 Oct;23(3):534-9.
8504803	Ruetschi U, Dellsen A, Sahlin P, Stenman G, Rymo L, Lindstedt S: Human 4-hydroxyphenylpyruvate dioxygenase. Primary structure and chromosomal localization of the gene. Eur J Biochem. 1993 May 1;213(3):1081-9.
8521727	Stenman G, Roijer E, Ruetschi U, Dellsen A, Rymo L, Lindstedt S: Regional assignment of the human 4-hydroxyphenylpyruvate dioxygenase gene (HPD) to 12q24-->qter by fluorescence in situ hybridization. Cytogenet Cell Genet. 1995;71(4):374-6.

# Drug_Target_1_HGNC_ID:
HGNC:5147

# Drug_Target_1_HPRD_ID:
02041

# Drug_Target_1_ID:
506

# Drug_Target_1_Locus:
12q24-qter

# Drug_Target_1_Molecular_Weight:
44804

# Drug_Target_1_Name:
4-hydroxyphenylpyruvate dioxygenase

# Drug_Target_1_Number_of_Residues:
392

# Drug_Target_1_PDB_ID:
1SQI

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00903	Glyoxalase

# Drug_Target_1_Protein_Sequence:
>4-hydroxyphenylpyruvate dioxygenase
TTYSDKGAKPERGRFLHFHSVTFWVGNAKQAASFYCSKMGFEPLAYRGLETGSREVVSHV
IKQGKIVFVLSSALNPWNKEMGDHLVKHGDGVKDIAFEVEDCDYIVQKARERGAKIMREP
WVEQDKFGKVKFAVLQTYGDTTHTLVEKMNYIGQFLPGYEAPAFMDPLLPKLPKCSLEMI
DHIVGNQPDQEMVSASEWYLKNLQFHRFWSVDDTQVHTEYSSLRSIVVANYEESIKMPIN
EPAPGKKKSQIQEYVDYNGGAGVQHIALKTEDIITAIRHLRERGLEFLSVPSTYYKQLRE
KLKTAKIKVKENIDALEELKILVDYDEKGYLLQIFTKPVQDRPTLFLEVIQRHNHQGFGA
GNFNSLFKAFEEEQNLRGNLTNMETNGVVPGM

# Drug_Target_1_Reaction:
4-hydroxyphenylpyruvate + O2 = homogentisate + CO2

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P32754

# Drug_Target_1_SwissProt_Name:
HPPD_HUMAN

# Drug_Target_1_Synonyms:
4-hydroxyphenylpyruvic acid oxidase
4HPPD
EC 1.13.11.27
HPD
HPPDase

# Drug_Target_1_Theoretical_pI:
7.01

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00348
